Biotech shares are regarded as highly promising due to the innovative strength of the sector, but they also tend to be subject to drastic price fluctuations both ways. After a long period of consolidation, biotech shares have embarked on a clear upward trend since May 2018. Harald Kober, Senior Fund Manager, explains the reasons for the investors’ optimism.
230 Chinese A-shares have joined the important MSCI indices and share prices have rebounded from year-lows. Gabriela Tinti, Fund Manager, explains the relevance of the new A-shares.
In this interview Anton Hauser, senior fund manager at Erste Asset Management and expert for Central and East European (CEE) government bonds , talks about the difficult first half of 2018 and illustrates possible future scenarios.